ADVFN - Advanced Financial Network.
HOME» NYSE » A » AGN Stock Price » AGN Stock News

Allergan Share News

 Allergan, Stock Price
AGN Stock Price
 Allergan, Stock Chart
AGN Stock Chart
 Allergan, Stock News
AGN Stock News
 Allergan, Company Information
AGN Company Information
 Allergan, Stock Trades
AGN Stock Trades

Inspire Pharma: Dry-Eye Treatment Didn't Meet Study Endpoints

DOW JONES NEWSWIRES Inspire Pharmaceuticals Inc. (ISPH) said its Prolacria treatment for dry eye met neither the primary nor secondary endpoints in a late-stage trial. Shares fell 7.5% to $6.11 premarket. Shares in its partner in developing the eye drops, Allergan Inc. (AGN), weren't active after closing Wednesday at $61.20. Early data about Prolacria had been discouraging, so the final results won't come as a huge surprise, but the treatment had been one of Inspire's most advanced drugs in its pipeline. Its other advanced drug candidate is denufosol tetrasodium for cystic fibrosis. Inspire focuses on developing treatments for ophthalmic and pulmonary diseases. Chief Executive Christy Shaffer said Inspire has reported the results to Allergan and "will be conducting a thorough review of the program before determining next steps, if any." At the end of the six-week study, Inspire gauged subjects extent of dry eye with a "staining score," in which patterns made by a stain are used to measure damaged cells in the central area of the cornea. It aimed to have a proportion of its subjects receiving Prolacria have a staining score of zero compared to a placebo group, its primary endpoint. It also failed to reduce the staining score by two units compared to the control group, the secondary endpoint. Dry eye occurs when the eye isn't being sufficiently lubricated. In November, the drug company reported a narrower third-quarter loss thanks to double-digit growth in sales. -By Joan E. Solsman, Dow Jones Newswires; 212-416-2291;

Stock News for Allergan (AGN)
11/25/201512:24:00Correction to Barron's Friday Blog Item on Pfizer-Allergan
11/25/201511:14:00Allergan Reaches Settlement with New York Attorney General's...
11/25/201510:10:00Pfizer's Lyrica Fails to Treat Traumatic Neuropathic Pain
11/25/201509:59:00Pfizer's Lyrica Fails to Treat Traumatic Neuropathic Pain
11/25/201508:00:00Allergan and Rugen Therapeutics Announce Collaboration to Discover...
11/25/201503:02:00Is Pfizer's Deal Good For Ireland?
11/25/201503:02:00Skadden's Tax Work Anything But Dull
11/24/201508:54:02Here's What Pfizer Is Really Buying With Its Purchase of Allergan
11/24/201508:33:00Pfizer's Allergan Deal Offers Ireland Few New Benefits
11/24/201506:04:05Current Report Filing (8-k)
11/24/201503:02:00With Merger Looming, Pfizer Weighs Plan To Split In Two
11/23/201518:20:00Vodafone Postpones a Bond Sale
11/23/201517:23:00Pfizer Inversion Puts Pressure on U.S. Lawmakers to Revamp Tax...
11/23/201516:57:00While Pfizer Gets a Tax Break, Many Investors Face a Hit -- Update
11/23/201516:21:00While Pfizer Gets a Tax Break, Its Investors Face a Hit
11/23/201514:44:00Pfizer Inversion Puts Pressure on U.S. Lawmakers to Revamp Tax...
11/23/201513:31:00Pfizer Inversion Puts Pressure on U.S. Lawmakers to Revamp Tax...
11/23/201512:04:00Pfizer and Allergan Strike $155 Billion Inversion Deal--5th Update
11/23/201510:50:00Pfizer and Allergan Strike $155 Billion Inversion Deal--4th Update
11/23/201509:15:02Current Report Filing (8-k)

Allergan and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations